Bertaux, M.; Luo, C.; Radulescu, C.; Beuzeboc, P.; Landais, C.; Touche, P.; Abraham, C.; Seban, M.H.; Camps, E.; Faucheron, A.;
et al. Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients. Pharmaceuticals 2025, 18, 701.
https://doi.org/10.3390/ph18050701
AMA Style
Bertaux M, Luo C, Radulescu C, Beuzeboc P, Landais C, Touche P, Abraham C, Seban MH, Camps E, Faucheron A,
et al. Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients. Pharmaceuticals. 2025; 18(5):701.
https://doi.org/10.3390/ph18050701
Chicago/Turabian Style
Bertaux, Marc, Caroline Luo, Camelia Radulescu, Philippe Beuzeboc, Cecile Landais, Pauline Touche, Christine Abraham, Marie Homo Seban, Eve Camps, Antoine Faucheron,
and et al. 2025. "Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients" Pharmaceuticals 18, no. 5: 701.
https://doi.org/10.3390/ph18050701
APA Style
Bertaux, M., Luo, C., Radulescu, C., Beuzeboc, P., Landais, C., Touche, P., Abraham, C., Seban, M. H., Camps, E., Faucheron, A., Tourne, M., Fricot, L., Turpin, L., Seban, R.-D., & Khedairia, S.
(2025). Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients. Pharmaceuticals, 18(5), 701.
https://doi.org/10.3390/ph18050701
